Mizuho Securities USA LLC Decreases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mizuho Securities USA LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,770 shares of the medical research company’s stock after selling 4,658 shares during the quarter. Mizuho Securities USA LLC’s holdings in Thermo Fisher Scientific were worth $15,322,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. EP Wealth Advisors LLC increased its stake in Thermo Fisher Scientific by 2.3% in the 1st quarter. EP Wealth Advisors LLC now owns 14,175 shares of the medical research company’s stock worth $8,239,000 after buying an additional 316 shares in the last quarter. Westwood Holdings Group Inc. lifted its holdings in shares of Thermo Fisher Scientific by 54.9% in the 1st quarter. Westwood Holdings Group Inc. now owns 1,233 shares of the medical research company’s stock valued at $717,000 after acquiring an additional 437 shares during the last quarter. Senator Investment Group LP bought a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $49,403,000. Brant Point Investment Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.4% in the 1st quarter. Brant Point Investment Management LLC now owns 15,025 shares of the medical research company’s stock valued at $8,733,000 after acquiring an additional 207 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.8% in the 1st quarter. Stonebridge Capital Advisors LLC now owns 24,864 shares of the medical research company’s stock valued at $14,451,000 after acquiring an additional 198 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on TMO shares. TD Cowen increased their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Barclays decreased their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. Bernstein Bank lifted their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Finally, Bank of America lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Insider Activity

In related news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the sale, the chief executive officer now owns 14,608 shares of the company’s stock, valued at $8,076,178.88. The trade was a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,150 shares of company stock valued at $20,651,865 in the last 90 days. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.7 %

Shares of Thermo Fisher Scientific stock opened at $512.86 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The company has a market capitalization of $196.17 billion, a price-to-earnings ratio of 32.15, a P/E/G ratio of 3.37 and a beta of 0.79. The business has a fifty day simple moving average of $579.63 and a two-hundred day simple moving average of $580.98. Thermo Fisher Scientific Inc. has a 1 year low of $476.45 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.69 earnings per share. Research analysts forecast that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a $0.39 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its board has approved a share repurchase plan on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.